Stephen A. Harrison

70.1k citations
502 papers · 54.0k · 48 hit papers · h-index 103

Impact in

  • Hepatology top 0.02%
    • Liver Disease and Transplantation
    • Liver Diseases and Immunity
    • Hepatitis C virus research
  • Epidemiology top 0.01%
    • Liver Disease Diagnosis and Treatment

Papers in

    • Liver Disease Diagnosis and Treatment 300
    • Hepatitis C virus research 57
    • Liver Diseases and Immunity 44
    • Liver Disease and Transplantation 37
    • Hepatocellular Carcinoma Treatment and Prognosis 26

Stephen A. Harrison

480 papers receiving 52.6k citations

Stephen A. Harrison's Hit Papers

Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study 2024 · 111 citations
1110+1+2Years since publication50010001.5k2.0k

Peers

Stephen A. Harrison
Comparison fields: 5 of 195
  • Hepatology 12.7k
  • Epidemiology 38.2k
  • Endocrinology, Diabetes and Metabolism 13.6k
  • Pathology and Forensic Medicine 3.9k
  • Cell Biology 3.7k
Replace Quentin Mark Anstee with:
Quentin Mark Anstee United Kingdom
Elisabetta Bugianesi Italy
Luca V. C. Valenti Italy
Philip Noel Newsome United Kingdom
Christopher D Byrne United Kingdom
Linda Henry United States
Michael Trauner Austria
Srinivasan Dasarathy United States
Vijay H. Shah United States
Helen H. Hobbs United States
Stephen A. Harrison relative to Quentin Mark Anstee United Kingdom Quentin Mark Anstee's profile →
Citations per field
00.5×1.6×
Quentin Mark Anstee · 1×
Citations per year

Countries citing papers authored by Stephen A. Harrison

Since Specialization
Citations

This map shows the geographic impact of Stephen A. Harrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen A. Harrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen A. Harrison more than expected).

Fields of papers citing papers by Stephen A. Harrison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen A. Harrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen A. Harrison. The network helps show where Stephen A. Harrison may publish in the future.

Co-authors

The 25 scholars most cited alongside Stephen A. Harrison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen A. Harrison Line = papers co-authored together Stephen A. Harrison links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 502 papers — load more, or switch the sort, to bring in the rest.

#Work
1
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Hit paper breakdown →
20175725
2
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
Hit paper breakdown →
20202571
3
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Hit paper breakdown →
20232138
4
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Hit paper breakdown →
20232013
5
Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
Hit paper breakdown →
20101822
6
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Hit paper breakdown →
20141547
7
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Hit paper breakdown →
20201544
8
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Hit paper breakdown →
20061541
9
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Hit paper breakdown →
20101162
10
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Hit paper breakdown →
20191063
11
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Hit paper breakdown →
2016911
12
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
Hit paper breakdown →
2008722
13
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Hit paper breakdown →
2019638
14
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Hit paper breakdown →
2023635
15
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Hit paper breakdown →
2021613
16
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis
Hit paper breakdown →
2003602
17
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Hit paper breakdown →
2017584
18
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Hit paper breakdown →
2018474
19
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Hit paper breakdown →
2021458
20 2003410

About Stephen A. Harrison

Stephen A. Harrison is a scholar working on Epidemiology, Hepatology, Endocrinology, Diabetes and Metabolism, Plant Science and Cell Biology, having authored 502 papers that have together received 54.0k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (300 papers), Diet, Metabolism, and Disease (65 papers), Hepatitis C virus research (57 papers), Wheat and Barley Genetics and Pathology (47 papers), Liver Diseases and Immunity (44 papers), Liver Disease and Transplantation (37 papers), Hepatocellular Carcinoma Treatment and Prognosis (26 papers) and Pancreatitis Pathology and Treatment (21 papers). The work is most often cited by research in Hepatology (12.7k citations), Epidemiology (38.2k citations), Endocrinology, Diabetes and Metabolism (13.6k citations), Pathology and Forensic Medicine (3.9k citations) and Cell Biology (3.7k citations). Stephen A. Harrison has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Arun Jayant Sanyal, Zobair M. Younossi, Kenneth J. Cusi, Dawn McDowell Torres, Elizabeth M. Brunt, Mary Eugenia Rinella, Naga Chalasani, Michael Charlton, Joel E. Lavine and Brent A. Neuschwander‐Tetri. Their work appears in journals such as Journal of Hepatology, Hepatology, Gastroenterology, Clinical Gastroenterology and Hepatology and The American Journal of Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact